Hengrui Medicine: Has not yet started to implement share repurchase.

Hengrui Pharmaceuticals announcement, as of August 31, 2025, the company has not yet started the implementation of share repurchases. The company's share repurchase plan was approved by the board of directors on August 20, 2025, agreeing to use its own funds to repurchase shares through centralized bidding trading, for the implementation of the A-share employee stock ownership plan. The repurchase price shall not exceed 90.85 yuan per share, with a total amount of funds not less than 1 billion yuan and not exceeding 2 billion yuan. The repurchase period shall be within 12 months from the date the board of directors approves the share repurchase plan.